These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 35758508)

  • 41. Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities.
    Parise CA; Caggiano V
    Breast Cancer Res Treat; 2017 May; 163(1):151-158. PubMed ID: 28213780
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Native American ancestry and breast cancer risk in Colombian and Mexican women: ruling out potential confounding through ancestry-informative markers.
    Zollner L; Torres D; Briceno I; Gilbert M; Torres-Mejía G; Dennis J; Bolla MK; Wang Q; Hamann U; Lorenzo Bermejo J
    Breast Cancer Res; 2023 Oct; 25(1):111. PubMed ID: 37784177
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
    Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
    BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women.
    Zavala VA; Casavilca-Zambrano S; Navarro-Vásquez J; Castañeda CA; Valencia G; Morante Z; Calderón M; Abugattas JE; Gómez H; Fuentes HA; Liendo-Picoaga R; Cotrina JM; Monge C; Neciosup SP; Huntsman S; Hu D; Sánchez SE; Williams MA; Núñez-Marrero A; Godoy L; Hechmer A; Olshen AB; Dutil J; Ziv E; Zabaleta J; Gelaye B; Vásquez J; Gálvez-Nino M; Enriquez-Vera D; Vidaurre T; Fejerman L
    Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1602-1609. PubMed ID: 35654312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
    Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
    JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
    Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
    [No Abstract]   [Full Text] [Related]  

  • 47. Variation in breast cancer subtypes with age and race/ethnicity.
    Parise CA; Bauer KR; Caggiano V
    Crit Rev Oncol Hematol; 2010 Oct; 76(1):44-52. PubMed ID: 19800812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014.
    Scott LC; Mobley LR; Kuo TM; Il'yasova D
    Cancer; 2019 Oct; 125(19):3412-3417. PubMed ID: 31282032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The joint contribution of tumor phenotype and education to breast cancer survival disparity between Hispanic and non-Hispanic white women.
    Boone SD; Baumgartner KB; Joste NE; Pinkston CM; Yang D; Baumgartner RN
    Cancer Causes Control; 2014 Mar; 25(3):273-82. PubMed ID: 24337810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification.
    Dong XF; Wang Y; Huang BF; Hu GN; Shao JK; Wang Q; Tang CH; Wang CQ
    Biomed Res Int; 2020; 2020():8823270. PubMed ID: 33134390
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study.
    Brouckaert O; Rudolph A; Laenen A; Keeman R; Bolla MK; Wang Q; Soubry A; Wildiers H; Andrulis IL; Arndt V; Beckmann MW; Benitez J; Blomqvist C; Bojesen SE; Brauch H; Brennan P; Brenner H; Chenevix-Trench G; Choi JY; Cornelissen S; Couch FJ; Cox A; Cross SS; Czene K; Eriksson M; Fasching PA; Figueroa J; Flyger H; Giles GG; González-Neira A; Guénel P; Hall P; Hollestelle A; Hopper JL; Ito H; Jones M; Kang D; ; Knight JA; Kosma VM; Li J; Lindblom A; Lilyquist J; Lophatananon A; Mannermaa A; Manoukian S; Margolin S; Matsuo K; Muir K; Nevanlinna H; Peterlongo P; Pylkäs K; Saajrang S; Seynaeve C; Shen CY; Shu XO; Southey MC; Swerdlow A; Teo SH; Tollenaar RAEM; Truong T; Tseng CC; van den Broek AJ; van Deurzen CHM; Winqvist R; Wu AH; Yip CH; Yu JC; Zheng W; Milne RL; Pharoah PDP; Easton DF; Schmidt MK; Garcia-Closas M; Chang-Claude J; Lambrechts D; Neven P
    Breast Cancer Res; 2017 Nov; 19(1):119. PubMed ID: 29116004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.
    Chen L; Li CI
    Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1666-72. PubMed ID: 26464428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Triple-negative breast cancers are increased in black women regardless of age or body mass index.
    Stead LA; Lash TL; Sobieraj JE; Chi DD; Westrup JL; Charlot M; Blanchard RA; Lee JC; King TC; Rosenberg CL
    Breast Cancer Res; 2009; 11(2):R18. PubMed ID: 19320967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
    Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
    Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic disparities in young patients based on breast cancer subtype: A population-based study from the SEER database.
    Chen B; Zhang X; Liu Y; Wang C
    Medicine (Baltimore); 2023 Mar; 102(13):e33416. PubMed ID: 37000095
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico.
    Ortiz AP; Frías O; Pérez J; Cabanillas F; Martínez L; Sánchez C; Capó-Ramos DE; González-Keelan C; Mora E; Suárez E
    Cancer Med; 2013 Jun; 2(3):343-50. PubMed ID: 23930211
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidemiology of Basal-like and Luminal Breast Cancers among Black Women in the AMBER Consortium.
    Benefield HC; Zirpoli GR; Allott EH; Shan Y; Hurson AN; Omilian AR; Khoury T; Hong CC; Olshan AF; Bethea TN; Bandera EV; Palmer JR; Ambrosone CB; Troester MA
    Cancer Epidemiol Biomarkers Prev; 2021 Jan; 30(1):71-79. PubMed ID: 33097496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
    Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
    BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.